IL-4Rα-lytic peptide

General Information


DRACP ID  DRACP00339

Peptide Name   IL-4Rα-lytic peptide

Sequence  KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK

Sequence Length  33

UniProt ID  Not available

PubChem CID  Not available

Origin  Interleukin-4 receptor a (IL-4Ra) chain

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
BxPC-3 Pancreatic ductal adenocarcinoma Carcinoma IC50=6.8 μmol/L WST-1 assay 24 h 1
SU.86.86 Pancreatic adenocarcinoma Carcinoma IC50=7.5 μmol/L WST-1 assay 24 h 1
KB Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=13.2 μmol/L WST-1 assay 24 h 1
T98G Glioblastoma Blastoma IC50=18.5 μmol/L WST-1 assay 24 h 1
A172 Glioblastoma Blastoma IC50=6.8 μmol/L WST-1 assay 24 h 1
NCI-H322 Minimally invasive lung adenocarcinoma Carcinoma IC50=3.6 μmol/L WST-1 assay 24 h 1
MDA-MB-231 Breast adenocarcinoma Carcinoma IC50=5.7 μmol/L WST-1 assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Targeting Interleukin-4 Receptor α

Affinity  Not available

Mechanism  The IL-4Rα–lytic peptide contains a target moiety to bind to IL-4Rα and a cellular toxic lytic peptide that selectively kills cancer cells

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  l=D-Leucine; k=D-Lysine

Chiral  Mix



Physicochemical Information


Formula  C154H271N47O28

Absent amino acids  ACEHMPSTVWY

Common amino acids  L

Mass  380012

Pl  12.34

Basic residues  11

Acidic residues  1

Hydrophobic residues  11

Net charge  10

Boman Index  -5506

Hydrophobicity  -45.15

Aliphatic Index  118.18

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22084165

Title  Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy

Doi 10.1158/1535-7163.MCT-11-0363

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.